XXII Fundamental Analysis - 22ND CENTURY GROUP INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to XXII. XXII was compared to 8 industry peers in the Tobacco industry. While XXII seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, XXII is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

XXII had negative earnings in the past year.

XXII had a negative operating cash flow in the past year.

XXII had negative earnings in each of the past 5 years.

In the past 5 years XXII always reported negative operating cash flow.

1.2 Ratios

XXII has a worse Return On Assets (-95.38%) than 87.50% of its industry peers.

Looking at the Return On Equity, with a value of -564.61%, XXII is doing worse than 62.50% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-95.38%
ROE	-564.61%
ROIC	N/A

ROA(3y)-239.28%

ROA(5y)-159.78%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XXII so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for XXII has been increased compared to 1 year ago.

XXII has more shares outstanding than it did 5 years ago.

XXII has a better debt/assets ratio than last year.

2.2 Solvency

XXII has an Altman-Z score of -26.98. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of XXII (-26.98) is worse than 75.00% of its industry peers.

XXII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-26.98

ROIC/WACCN/A

WACC5.22%

2.3 Liquidity

A Current Ratio of 0.68 indicates that XXII may have some problems paying its short term obligations.

XXII has a Current ratio of 0.68. This is in the lower half of the industry: XXII underperforms 75.00% of its industry peers.

XXII has a Quick Ratio of 0.68. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of XXII (0.52) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	0.68
Quick Ratio	0.52

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XXII shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.97%, which is quite impressive.

The Revenue for XXII has decreased by -19.76% in the past year. This is quite bad

The Revenue has been decreasing by -1.15% on average over the past years.

EPS 1Y (TTM)98.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.37%

Revenue 1Y (TTM)-19.76%

Revenue growth 3Y-7.64%

Revenue growth 5Y-1.15%

Sales Q2Q%93.13%

3.2 Future

XXII is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.81% yearly.

Based on estimates for the next years, XXII will show a very strong growth in Revenue. The Revenue will grow by 24.06% on average per year.

EPS Next Y5.25%

EPS Next 2Y41.81%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-12.73%

Revenue Next 2Y24.06%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 11.36, the valuation of XXII can be described as very reasonable.

75.00% of the companies in the same industry are more expensive than XXII, based on the Price/Forward Earnings ratio.

The average S&P500 Price/Forward Earnings ratio is at 36.28. XXII is valued rather cheaply when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	11.36

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates XXII does not grow enough to justify the current Price/Earnings ratio.

A more expensive valuation may be justified as XXII's earnings are expected to grow with 41.81% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.81%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XXII!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

22ND CENTURY GROUP INC

NASDAQ:XXII (8/5/2025, 8:00:02 PM)

After market: 2.51 -0.04 (-1.57%)

2.55

+0.09 (+3.66%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupFood, Beverage & Tobacco

GICS IndustryTobacco

Earnings (Last)05-13 2025-05-13/bmo

Earnings (Next)08-11 2025-08-11

Inst Owners3.97%

Inst Owner Change0%

Ins Owners26.38%

Ins Owner Change0.49%

Market Cap1.27M

Analysts82.86

Price Target64.52 (2430.2%)

Short Float %N/A

Short Ratio0.16

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-15.75%

Min Revenue beat(2)-55.74%

Max Revenue beat(2)24.24%

Revenue beat(4)1

Avg Revenue beat(4)-17.1%

Min Revenue beat(4)-55.74%

Max Revenue beat(4)24.24%

Revenue beat(8)1

Avg Revenue beat(8)-22.16%

Revenue beat(12)3

Avg Revenue beat(12)-21.35%

Revenue beat(16)4

Avg Revenue beat(16)-17.18%

PT rev (1m)427.08%

PT rev (3m)427.08%

EPS NQ rev (1m)52.63%

EPS NQ rev (3m)-989.47%

EPS NY rev (1m)61.86%

EPS NY rev (3m)-777.21%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.74%

Revenue NY rev (1m)0%

Revenue NY rev (3m)2.67%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	11.36
P/S	0.05
P/FCF	N/A
P/OCF	N/A
P/B	0.35
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2825.6

EYN/A

EPS(NY)0.22

Fwd EY8.8%

FCF(TTM)-30.56

FCFYN/A

OCF(TTM)-30.13

OCFYN/A

SpS47.74

BVpS7.25

TBVpS-4.98

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-95.38%
ROE	-564.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-239.28%

ROA(5y)-159.78%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover1.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	22.16%
Cap/Sales	0.89%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.68
Quick Ratio	0.52
Altman-Z	-26.98

F-Score5

WACC5.22%

ROIC/WACCN/A

Cap/Depr(3y)104.4%

Cap/Depr(5y)87.56%

Cap/Sales(3y)9.68%

Cap/Sales(5y)6.87%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)98.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.37%

EPS Next Y5.25%

EPS Next 2Y41.81%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-19.76%

Revenue growth 3Y-7.64%

Revenue growth 5Y-1.15%

Sales Q2Q%93.13%

Revenue Next Year-12.73%

Revenue Next 2Y24.06%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y69.68%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year57.74%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y77.32%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y75.42%

OCF growth 3YN/A

OCF growth 5YN/A

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens